Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — 9M 2020 Earnings Presentation
16 slides from Zealand Pharma A/s's earnings presentation, Nov 13, 2020
Slide 1: 9M 2020 Interim report
9M 2020 Interim report 12 November 2020
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand”). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 3: Advancing the pipeline and preparing first commercial launch
Advancing the pipeline and preparing first commercial launch Business highlights for Q3 2020 and subsequent events • Completed phase 1a single-ascending dose trial with ZP7570 (pINN: dapiglutide) demonstrating safety and tolerability and plasma half-life allowing for once weekly dosing. Dosed first
Slide 4: HypoPal targets growing market
HypoPal® targets growing market U.S. rescue kit market 350 • ~10% annual market growth following new entrant launches in 2019 300 250 • New entrants have captured approximately ~40% volume market share through 2020 Market volume largely driven by Type 1 Diabetes utilization (80% of TRx), with additi
Slide 5: Most clinical programs progressing as planned despite COVID-19
Most clinical programs progressing as planned despite COVID-19 Safety of our people Taking precautions to keep our employees, patients and business and clinical partners safe. To the extent possible, employees are working from home Research activities Clinical trials HCP and patient engagement Adjus
Slide 6: Income statement
Income statement 6 9M 2020 presentation 12 November 2020 DKK thousand 9M 2020 9M 2019 Revenue 289,958 29,840 Gross margin 227,661 29,425 Research and Development expenses -430,991 -380,733 Sales and Marketing Expenses -172,282 0 Administrative Expenses -111,232 -51,211 Operating result -449,120 -4
Slide 7: Strong financial position allows for continued investments
Strong financial position allows for continued investments Net Operating Expenses Cash position DKK 714.5 million / USD 112.3 million DKK 1.53 billion / USD 240.4 million DKKm DKKm 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0 1,800,000 1,600,000 1,400,000 1,200,000 1,000,000 800
Slide 8: 2020 financial guidance maintained
2020 financial guidance maintained • In 2020, Zealand Pharma expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand does not intend to provide guidance on such revenue • Net product revenue from the sales of the V-Go wearable i
Slide 9: Pipeline
Pipeline 1: Partnered with Boehringer Ingelheim. 2: Partnered with Alexion Pharmaceuticals. 3: Acquired Encycle Therapeutics, Inc.: future potential earn-outs of up to US $80 million contingent on successful achievement of development, regulatory and commercial milestones; payable in cash and/or ZEA
Slide 10: Congenital hyperinsulinism
Congenital hyperinsulinism An ultra-rare and devastating congenital disorder in new-borns (CHI) Insulin overproduction CHI is caused by a defect in pancreatic beta cells, resulting in insulin overproduction. This leads to persistently and dangerously low blood sugar levels (hypoglycemia) 1: Thelansi
Slide 11: Ph3-program spanning newborns to 12-year olds
Ph3-program spanning newborns to 12-year olds Trial 17109 Trial 17103 Open-label extension study 17106 32 patients, age 3 months-12 years. Enrollment complete 12 patients, age 7 days-12 months. First patients enrolled Maximum 44 patients, age 1 month onwards Hypo-prone, maximum therapy, incl. pancre
Slide 12: First phase data read-out expected in December
First phase 3 data read-out expected in December 17109 Trial design Primary endpoint • Hypoglycemia event rate, defined as average weekly number of hypoglycemic events (PG <70 mg/dL or 3.9 mmol/L) during Weeks 2-4, as detected by self-monitored PG (SMPG) Key secondary efficacy endpoints • Increase i
Slide 13: Long-term commitment to improve SBS-treatment
Long-term commitment to improve SBS-treatment High unmet medical need Glepaglutide Dapiglutide* (ZP7570) Long-acting GLP-1/ GLP-2 dual agonist4 Pivotal phase 3 trial ongoing Rare and severe disease affecting up to 40,000 people in the U.S. and Europe1,2 that impairs intestinal absorption, diarrhea a
Slide 14: Advancing clinical development of dapiglutide
Advancing clinical development of dapiglutide Completed ph1a single-ascending dose trial Ph1b multi-ascending dose trial ongoing Observed plasma half-life allowing for once weekly dosing Trial initiated in November 2020 Evaluate safety, tolerability, PK and biomarkers following repeated dosing In th
Slide 15: 2020 is a significant year for Zealand Pharma
2020 is a significant year for Zealand Pharma treatment solutions and Marlborough Late-stage assets and Three late-stage assets for metabolic 15 9M 2020 presentation 12 November 2020 5x25 5 commercialized products by 2025 Fully integrated biotech with U.S. commercial presence We are passionate abo
Slide 16: Q&A session
Q&A session• 16 9M 2020 presentation 12 November 2020